SUMMIT, N.J.–(BUSINESS WIRE)– March 05, 2019 – Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority…Original Article
U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
